15 July 2002
Ligands of the peroxisome proliferator-activated receptor-PPAR-α reduce myocardial infarct size
Nicole S. Wayman, Belinda L. Ellis, Christoph ThiemermannMed Sci Monit 2002; 8(7): BR243-247 :: ID: 13612
Abstract
Background: This study was designed to investigate the effects of two, chemically distinct activators of PPAR-α (clofibrate and WY14643) in a rat model of acute myocardial infarction.
Material/Methods: Male Wistar rats were anesthetized with sodium thiopentone (120 mg/kg i.v.) and subjected to regional myocardial ischemia (for 25 min) and reperfusion (for 2 h). Area at risk was determined by injection of Evans Blue dye and infarct size after staining with nitroblue tetrazolium.
Results: Pre-treatment of rats with the PPAR-α agonists clofibrate (0.3 mg/kg) caused a significant reduction in myocardial infarct size of 43%. Similarly, pre-treatment of rats with the PPAR-α agonists WY14643 (1 mg/kg) caused a significant reduction in myocardial infarct size of 43%.
Conclusions: Taken together, these results show that ligands of PPAR-α reduce the tissue necrosis associated with acute myocardial infarction. We propose that fibrates and other PPAR-α agonists
may be useful in conditions associated with ischemia-reperfusion of the heart and other organs.
Keywords: Cardiotonic Agents - pharmacology, Clofibrate - pharmacology, Heart - drug effects, Hemodynamic Processes, Ligands, Myocardial Infarction - metabolism, Myocardium - metabolism, Myocardium - pathology, Peroxisome Proliferators - pharmacology, Pyrimidines - pharmacology, Rats, Wistar, Receptors, Cytoplasmic and Nuclear - agonists, Receptors, Cytoplasmic and Nuclear - metabolism, Transcription Factors - agonists, Transcription Factors - metabolism
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952